Efficacy and safety of Buxus sempervirens L. preparations (SPV(30)) in HIV-infected asymptomatic patients: a multicentre, randomized, double-blind, placebo-controlled trial

J Durant; P Chantre; G Gonzalez; J Vandermander; P Halfon; B Rousse; D Guédon; V Rahelinirina; S Chamaret; L Montagnier; P Dellamonica

doi:10.1016/S0944-7113(98)80052-4

Efficacy and safety of Buxus sempervirens L. preparations (SPV(30)) in HIV-infected asymptomatic patients: a multicentre, randomized, double-blind, placebo-controlled trial

Phytomedicine. 1998 Mar;5(1):1-10. doi: 10.1016/S0944-7113(98)80052-4.

Authors

J Durant¹, P Chantre, G Gonzalez, J Vandermander, P Halfon, B Rousse, D Guédon, V Rahelinirina, S Chamaret, L Montagnier, P Dellamonica

Affiliation

¹ L'Archet Centre Hospitalier Universitaire de Nice, France.

PMID: 23195692
DOI: 10.1016/S0944-7113(98)80052-4

Abstract

The objective of the present study was to compare the efficacy and safety of two doses of SPV(30) in HIV asymptomatic patients. The study was designed as a randomized double-blind multicentre trial of two doses of SPV(30) (990 mg/d and 1980 mg/d) versus placebo. 145 previously untreated subjects with asymptomatic HIV infection (CDC group IV) and CD4 cell counts between 250 and 500 × 10(6)/1 were recruited. There was a statistically significant difference in therapeutic failures between groups in favor of SPV(30) 990 mg including decreases of CD4 cell count < 200 × 10(6)/1 and/or number of clinical aggravations (progression to AIDS or AIDS related complex). The treatment groups differed statistically in the rate of disease progression also in favor of SPV(30) 990 mg/d. Fewer patients receiving SPV(30) 990 mg/d had at the end an increase of viral load greater than 0.5 log (P = 0.029). No severe side-effects were reported in the 3 groups. From these results we conclude that SPV(30) 990 mg/d has beneficial effects in HIV asymptomatic patients and appears to delay the progression of HIV disease.